Over the last 5 years we have witnessed revolutionary improvements in the first-line setting for advanced non-small-cell lung cancer (NSCLC): the introduction of combinations with platinum-doublets and immunotherapy as standard treatment of treatment-naive NSCLC has led to better response rates and overall survival (OS).1-5
No takes yet. Share an insight, caveat, or question.
Moliner et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: